benserazide has been researched along with Tremor in 17 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Tremor: Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intention or action tremor, a common manifestation of CEREBELLAR DISEASES, is aggravated by movement. In contrast, resting tremor is maximal when there is no attempt at voluntary movement, and occurs as a relatively frequent manifestation of PARKINSON DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced parkinsonian symptoms, predominantly bradykinesia and tremor, in marmosets." | 3.67 | Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. ( Close, SP; Marriott, AS; Pay, S, 1985) |
| "A myoclonic syndrome consisting of tremor, myoclonus, and seizures was produced following the systemic administration of 5-hydroxytryptophan to adult rats previously given intracisternal injections of 5,7-dihydroxytryptamine and systemic desmethylimipramine, but not in their controls." | 3.65 | Myoclonus after 5-hydroxytryptophan in rats with lesions of indoleamine neurons in the central nervous system. ( Baldessarini, RJ; Cancian, D; Growdon, JH; Stewart, RM, 1976) |
| "Tremor was assessed via accelerometry and surface EMG." | 2.68 | 'Atypical' tremor. ( Byth, K; Einstein, R; Henderson, JM; Jackson, DM; Morris, JG, 1995) |
| "In the Parkinson's disease group studied, the frequency, EMG pattern of bursts, and response to L-Dopa were similar for the two tremors (median improvement of RT by 70% and PT by 61%)." | 2.67 | Postural tremor of Parkinson's disease. ( Byth, K; Einstein, R; Henderson, JM; Jackson, D; Morris, JG; Yiannikas, C, 1994) |
| "In 3 patients with longstanding Parkinson's disease treated with Madopar or Nacom, who were not included in the study, the doses of the above drugs could be maintained or reduced by addition of deprenyl." | 2.66 | Levodopa and monoamine oxidase inhibitor combination therapy. A controlled clinical trial. ( Grundmann, M; Schimrigk, K, 1987) |
| "Parkinson's disease is clinically defined by bradykinesia, along with rigidity and tremor." | 1.56 | Effects of dopamine on reinforcement learning in Parkinson's disease depend on motor phenotype. ( Cools, R; den Ouden, HEM; Dirkx, MF; Helmich, RC; Toni, I; van Nuland, AJ; Zach, H, 2020) |
| "Re-emergent tremor is a continuation of resting tremor during stable posturing, and it has a dopaminergic basis." | 1.48 | The nature of postural tremor in Parkinson disease. ( Bloem, BR; Dirkx, MF; Hallett, M; Helmich, RC; Zach, H, 2018) |
| "In this case report, we describe a Parkinson's disease (PD) patient with limb-kinetic apraxia (LKA) in whom degeneration of the corticofugal tract (CFT) from the supplementary motor area (SMA) was observed in diffusion tensor tractography (DTT)." | 1.46 | Degeneration of the corticofugal tract from the secondary motor area in a Parkinson's disease patient with limb-kinetic apraxia: A case report. ( Chang, MC; Lee, HD, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (52.94) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Che, NN | 1 |
| Chen, SY | 1 |
| Li, X | 1 |
| Ma, JJ | 1 |
| Yang, HQ | 1 |
| van Nuland, AJ | 1 |
| Helmich, RC | 2 |
| Dirkx, MF | 2 |
| Zach, H | 2 |
| Toni, I | 1 |
| Cools, R | 1 |
| den Ouden, HEM | 1 |
| Lee, HD | 1 |
| Chang, MC | 1 |
| Bloem, BR | 1 |
| Hallett, M | 1 |
| Dick, OE | 1 |
| Romanov, SP | 1 |
| Nozdrachev, AD | 1 |
| Agnoli, A | 1 |
| Ruggieri, S | 1 |
| Baldassarre, M | 1 |
| Rocco, A | 1 |
| Del Roscio, S | 1 |
| D'Urso, R | 1 |
| Mearelli, S | 1 |
| Falaschi, P | 1 |
| Frajese, G | 1 |
| Albani, C | 1 |
| Buck, A | 1 |
| Henderson, JM | 2 |
| Einstein, R | 2 |
| Jackson, DM | 1 |
| Byth, K | 2 |
| Morris, JG | 2 |
| Yiannikas, C | 1 |
| Jackson, D | 1 |
| Stewart, RM | 1 |
| Growdon, JH | 1 |
| Cancian, D | 1 |
| Baldessarini, RJ | 1 |
| Rondot, P | 2 |
| Bathien, N | 1 |
| Dumas, JL | 1 |
| Grundmann, M | 1 |
| Schimrigk, K | 1 |
| Close, SP | 1 |
| Marriott, AS | 1 |
| Pay, S | 1 |
| Dumas, RJ | 1 |
| Birkmayer, W | 1 |
| Linauer, W | 1 |
| Mentasti, M | 1 |
| Riederer, P | 1 |
| Ungerstedt, U | 1 |
| Fuxe, K | 1 |
| Goldstein, M | 1 |
| Battista, A | 1 |
| Ogawa, M | 1 |
| Anagnoste, B | 1 |
| Derkach, P | 1 |
| Larochelle, L | 1 |
| Bieger, D | 1 |
| Hornykiewicz, O | 1 |
5 trials available for benserazide and Tremor
| Article | Year |
|---|---|
'Atypical' tremor.
Topics: Benserazide; Child; Child, Preschool; Cross-Over Studies; Double-Blind Method; Drug Combinations; El | 1995 |
Postural tremor of Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Benserazide; Electromyography; Female; Humans; Levodopa; Male; Mi | 1994 |
Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications.
Topics: Adult; Aged; Benserazide; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Levodopa; Male; | 1975 |
Levodopa and monoamine oxidase inhibitor combination therapy. A controlled clinical trial.
Topics: Aged; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; | 1987 |
[2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
Topics: Benserazide; Carboxy-Lyases; Clinical Trials as Topic; Dermatitis, Seborrheic; Dihydroxyphenylalanin | 1974 |
12 other studies available for benserazide and Tremor
| Article | Year |
|---|---|
Autoimmune-mediated secondary-parkinsonism presented with micrographia and cognitive impairment.
Topics: Adult; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Antiparkinson Agents; Autoantibodies; Benser | 2021 |
Effects of dopamine on reinforcement learning in Parkinson's disease depend on motor phenotype.
Topics: Aged; Antiparkinson Agents; Benserazide; Computer Simulation; Conditioning, Operant; Dopamine Agonis | 2020 |
Degeneration of the corticofugal tract from the secondary motor area in a Parkinson's disease patient with limb-kinetic apraxia: A case report.
Topics: Anisotropy; Antiparkinson Agents; Benserazide; Diffusion Tensor Imaging; Drug Combinations; Female; | 2017 |
The nature of postural tremor in Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Cluster Analysis; Dopamine; Drug | 2018 |
Analysis of differences between physiological and pathological tremor of human fingers.
Topics: Antiparkinson Agents; Benserazide; Drug Combinations; Electromyography; Fingers; Humans; Isometric C | 2010 |
Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
Topics: Aged; Apomorphine; Benserazide; Bromocriptine; Carbidopa; Female; Humans; Levodopa; Male; Middle Age | 1980 |
Early detection of L-dopa response in parkinsonian patients with a standardized tracking test.
Topics: Adult; Basal Ganglia; Benserazide; Dose-Response Relationship, Drug; Drug Combinations; Female; Huma | 1993 |
Myoclonus after 5-hydroxytryptophan in rats with lesions of indoleamine neurons in the central nervous system.
Topics: 5-Hydroxytryptophan; Animals; Benserazide; Brain; Dose-Response Relationship, Drug; Drug Interaction | 1976 |
Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1985 |
[Dopamine and abnormal movements].
Topics: Benserazide; Body Weight; Carboxy-Lyases; Dihydroxyphenylalanine; Drug Therapy, Combination; Electro | 1972 |
Action of m-tyrosine in experimental models: evidence for possible antiparkinsonian activity.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Brain Chemistry; Denervation; Dihydrox | 1973 |
L-DOPA-chlorpromazine antagonism on running activity in mice.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Body Weight; Chlorpromazine; Dih | 1974 |